ALK rearrangements were detected in 3.85%, 4.31%, 5.72% and 12.39% of NSCLC patients with tumor stage of I (30 articles: 199/5168), II (25 articles: 50/1161), III (27 articles: 119/2080) and IV (28 articles: 214/1727), respectively (Table S2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.